Research Projects All Projects
Projects

Quick links

Testing of patient-derived stem cell extracellular vesicles loaded with drugs in a personalized lung-cancer on-chip platform (LoC4Ev)

Project Title: Testing of patient-derived stem cell extracellular vesicles loaded with drugs in a personalized lung-cancer on-chip platform (LoC4Ev).”

Funding: European Regional Development Fund (ERDF), Measure 1.1.1.1 “Support for applied research”

Project No.: 1.1.1.1/20/A/124

Period: 1 February 2021 – 30 November 2023

Project costs: 540 540.53 EUR

Principle Investigator: Dr. biol. Artūrs Ābols

Cooperation partner: SIA “Cellboxlab” 

 

Project summary:

This project aims to develop a personalised NSCLC patient lung cancer on chip (LCoC) and lung on chip (LoC) as a model system where to test the efficacy of drug-loaded patient-derived MSC produced EVs compared to the drug by itself.

Over half of the people diagnosed with lung cancer die within a year of diagnosis and the 5-year survival rate is less than 18%. Non-small cell lung cancer (NSCLC) accounts for the majority of all lung cancer cases. Depending on the stage of lung cancer, patients are eligible for certain treatments ranging from surgery to radiation to chemotherapy as well as targeted therapy. Thanks to genetic screening, specific mutations have been identified as a better target treatment for individual patients in the last decade. Also, there are molecular targeted therapies, that are not yet tested in lung cancer but could be applied in NSCLC cases where tumours have certain genetic variation. While there are options for different treatment, there is still a room for improvements in drug delivery, that could increase specificity and therefore decrease necessary concentrations and subsequently side effects of drugs. Extracellular vesicles (EV) have a natural ability to carry functional biomolecules, such as RNA, DNA, proteins and different metabolites in their lumen. This property makes EVs attractive for use in drug delivery. Indeed, several studies are currently underway to develop methods of exploiting EV for use as efficient drug delivery vehicles especially those derived from mesenchymal stem cells (MSC) due to their natural tumour cell tropism. However, current approaches have been tested only in simple in-vitro models or animal models. Next step would be testing these approaches into more advanced - personalised in vitro systems such as organs on chip platform

Information published 01.02.2021.

 

Progress of the project:

1 February 2021 – 30 April 2021

This reporting period, we started to prepare CMEK permit application for patient sample collection. Agreed on protocols for patient sample collection with doctors. Planning of the protocols for the isolation of lung cancer cells and the formation of organoids from patient surgery samples and the isolation of normal fibroblasts and their reprogramming into induced pluripotent stem cells (iPSC). Protocols for iPSC differentiation into lung epithelium, endothelium, and induced mesenchymal stem cells are also being developed. Lists of reagents for the necessary experiments are compiled. In parallel, the introduction of stem cell-derived extracellular vesicles (ASC52telo) into the first lung cancer on chip (LCOC) prototypes developed using stable cell lines A549 and HUVEC are being tested.

Information published 30.04.2021. 



Mājas lapas izstrādi finansēja ERAF 2.1.1.2. aktivitātes projekts Nr. 2010/0196/2DP/2.1.1.2.0/10/APIA/VIAA/004 "Latvijas biomedicīnas pētījumu integrācija Eiropas zinātnes telpā".